BACKGROUND: Inhibition of fibroblast (FB) proliferation and hyaluronic acid (HA) production may be a therapeutic approach to Graves' ophthalmopathy (GO). The flavonoid quercetin has a wide range of activities, including reduction of FB growth. AIM: To investigate the effects of quercetin in orbital FB from GO patients and control subjects. METHODS: Primary cultures of orbital FB were treated with quercetin or with its glycosides rutin and quercitrin. Cell proliferation, necrosis, apoptosis, HA production, and cell cycle were measured. RESULTS: Beginning at a 30 μM concentration, quercetin, but not rutin and quercitrin, reduced cell proliferation, with no difference between GO and control FB. The effect of quercetin on proliferation was due to necrosis and cell cycle blockade, whereas apoptosis was unaffected. Quercetin reduced HA in the cell media, with no difference between GO and control FB. CONCLUSIONS: Quercetin reduces cell proliferation and HA release in orbital FB. Whether these initial findings have any potential for the use of quercetin in the clinical practice remains to be established.
BACKGROUND: Inhibition of fibroblast (FB) proliferation and hyaluronic acid (HA) production may be a therapeutic approach to Graves' ophthalmopathy (GO). The flavonoidquercetin has a wide range of activities, including reduction of FB growth. AIM: To investigate the effects of quercetin in orbital FB from GO patients and control subjects. METHODS: Primary cultures of orbital FB were treated with quercetin or with its glycosidesrutin and quercitrin. Cell proliferation, necrosis, apoptosis, HA production, and cell cycle were measured. RESULTS: Beginning at a 30 μM concentration, quercetin, but not rutin and quercitrin, reduced cell proliferation, with no difference between GO and control FB. The effect of quercetin on proliferation was due to necrosis and cell cycle blockade, whereas apoptosis was unaffected. Quercetin reduced HA in the cell media, with no difference between GO and control FB. CONCLUSIONS:Quercetin reduces cell proliferation and HA release in orbital FB. Whether these initial findings have any potential for the use of quercetin in the clinical practice remains to be established.
Authors: M Marinò; E Morabito; M A Altea; E Ambrogini; F Oliveri; M R Brunetto; L E Pollina; D Campani; P Vitti; L Bartalena; A Pincheral; C Marcocci Journal: J Endocrinol Invest Date: 2005-03 Impact factor: 4.256
Authors: Jin Hee Jung; Jeong Ok Lee; Ji Hae Kim; Soo Kyung Lee; Ga Young You; Sun Hwa Park; Ji Man Park; Eung-Kyun Kim; Pann-Ghill Suh; Jin Kyung An; Hyeon Soo Kim Journal: J Cell Physiol Date: 2010-05 Impact factor: 6.384
Authors: M Leo; F Maggi; G R Dottore; G Casini; P Mazzetti; M Pistello; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2016-12-16 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-12-18 Impact factor: 4.256
Authors: G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2017-06-27 Impact factor: 4.256
Authors: Vardaan Gupta; Christine L Hammond; Elisa Roztocil; Mithra O Gonzalez; Steven E Feldon; Collynn F Woeller Journal: Surv Ophthalmol Date: 2021-09-04 Impact factor: 6.197